Boehringer Ingelheim Unveils Diabetes Pipeline
...es which will further assess the full potential of linagliptin for the treatment of type 2 diabetes."
DPP-4 inhibitors are a newer class of oral hypoglycemics
that target the incretin hormones GLP-1 and GIP, which are believed to be involved with regulating blood sugar.(2)
Linagliptin is a compound di...
...agement of the disease either from too much or poorly timed insulin or oral hypoglycemics
or too much exercise, not enough food, or poor timing of either. If blood g...t care.
The most important is the hypoglycemic treatment with either oral hypoglycemics
and/or insulin therapy. Nowadays, the goal for diabetics is to avoid or min...